Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
about
A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.The past, present, and future of basal insulins.Attenuated Suppression of Lipolysis Explains Increases in Triglyceride Secretion and Concentration with Basal Insulin Peglispro (BIL) Relative to Insulin Glargine Treatment in Patients with Type 1 Diabetes.Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response.Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomesHow Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes.Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1.Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3.Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.Hepato-preferential insulins: Is this the end, or the end of the beginning?In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro.A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial.Discontinued drug therapies to treat diabetes in 2015.Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
P2860
Q30978373-4F653CD1-32AD-4CFC-8DB0-E5AE0BC8C1B4Q36361469-2473ABE1-DBA2-4E35-A515-CEE3F5315018Q36554243-1824012E-A634-4AC8-AC0D-08B0AF960F8FQ36907339-50F6AB9A-D9C5-4D08-9472-72C83235D558Q37352359-6AEF3D80-D177-46F3-9E7C-61EED87A440BQ37394470-584A5B86-3AF4-45B8-9D92-1817B66CEFBDQ38176677-9BE79DD0-DC77-4A04-A712-9AA554521C2EQ38618376-D92E86D0-3CF7-4B8F-80F6-C1A2AA1F607AQ38620136-99B418C8-33BD-4F3A-B2CE-14954DB375A8Q38807485-84D10D28-BAB1-43DB-889B-878233A952CBQ38824504-49C60580-4C15-49E0-A0D0-72F5CB284A0FQ39023191-3436F795-358A-407B-91B5-D24BD60B5603Q39306199-FEFB6F05-9919-458B-B127-C6B5C4F519EFQ39533256-953CF9F6-B7EB-4246-BE61-A3A009103CDDQ39619624-EB350AE6-7F35-471F-A9AF-DB59E46F47CBQ41494572-3D32A31B-9BD7-440C-A5D3-1E048BE02959Q41673741-02C7A015-EC6D-4767-ADDE-55AF62485E28Q41673841-EFB22199-7BB6-4325-B7F2-1457936EC717Q42323189-3BCBB11A-168C-4FA6-B6D5-02EE47EB11AEQ42491076-18B1323A-CF4E-4503-B7D2-4CDAB881C489Q46001828-FEB92309-C760-4280-9BCC-091A9D0D51ADQ46150815-C8B39729-71EE-4073-A92B-E3C02CDD38C1Q46153484-F32CB743-9EA7-4EC7-A5BF-0F272D902BCEQ47436758-D3A1A7A1-AD1A-4E4F-A0A0-096851FC68E2Q51278143-FCE01209-FBF5-4A2F-8181-3EB22BBB7EA9Q51327624-571A98B0-C341-4AE7-BDE4-3B5ADAD963D5Q51410348-7623E903-8B26-4F12-9022-1CEC55F25424Q51597934-2E58CB67-B4D7-4F56-91BF-04C06C1E7943
P2860
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Steady-state pharmacokinetics ...... with type 2 diabetes mellitus.
@en
Steady-state pharmacokinetics ...... with type 2 diabetes mellitus.
@nl
type
label
Steady-state pharmacokinetics ...... with type 2 diabetes mellitus.
@en
Steady-state pharmacokinetics ...... with type 2 diabetes mellitus.
@nl
prefLabel
Steady-state pharmacokinetics ...... with type 2 diabetes mellitus.
@en
Steady-state pharmacokinetics ...... with type 2 diabetes mellitus.
@nl
P2093
P2860
P356
P1476
Steady-state pharmacokinetics ...... with type 2 diabetes mellitus.
@en
P2093
P2860
P304
P356
10.1111/DOM.12222
P577
2013-10-31T00:00:00Z